Merck CEO on melanoma vaccine results: The prescribing community will find results quite meaningful
CNBC Television · 3:51 · Watch on YouTube
Merck CEO Rob Davis defends the leaked phase 3 melanoma results for Moderna’s personalized neoantigen vaccine plus Keytruda: a 42% cut in recurrence or death versus Keytruda alone disappointed the market, but he argue...